SCHEMBL3340526

SCHEMBL3340526

Cc1c(I)ccc2nc(C(=O)O)cn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
GAA P10253 2/20 0.38
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 5/20 0.33
TDP1 Q9NUW8 2/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
ACMSD Q8TDX5 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
RAB9A P51151 3/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32
POLB P06746 1/20 0.32
ECE1 P42892 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369735 0.81 PTGS1 (0.41) PTGS1PTGS2GAARXFP1KDM4E
SCHEMBL2086528 0.81 PTGS1 (0.41) PTGS1PTGS2GAARXFP1KDM4E
SCHEMBL3366002 0.81 RAB9A (0.53) GAATDP1TSHRRAB9ANPC1
SCHEMBL3628721 0.78 KDM4E (0.51) PTGS1PTGS2GAAKDM4EALOX15
SCHEMBL3367405 0.78 PTGS1 (0.40) PTGS1PTGS2GAARXFP1KDM4E
SCHEMBL3498219 0.75 SMN1; SMN2 (0.47) GAAKDM4EGABRA2GABRB2RAB9A
SCHEMBL119926 0.73 GAA (0.66) PTGS1PTGS2GAAKDM4ETDP1
SCHEMBL3774255 0.73 TSHR (0.34) TSHRALDH1A1MAPTPOLB
SCHEMBL3718312 0.73 GAA (0.39) PTGS1PTGS2GAAKDM4ERAB9A
SCHEMBL2485937 0.72 PTGS1 (0.35) PTGS1PTGS2GAAKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 PTGS1 521/4885PTGS2 1294/4885GAA 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.